The Global Nonalcoholic Steatohepatitis Treatment Market, By Drug (Cenicriviroc, Elafibranor, Ocaliva, and Selonsertib), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 1,119.8 million in 2017 (based on existing approved therapies including anti-diabetics, vitamins, dietary supplements, and others) and is projected to exhibit a CAGR of 42.7% over the forecast period (2018 - 2026).
Nonalcoholic fatty liver disease (NAFLD) is a condition which occur due to the presence of fat in more than 5% of liver cells. NAFLD affects people who consume little or no alcohol. According to the Harvard Medical School, January 2018 report, NAFLD is the most common liver disease and affects nearly 25% of American adults, 60% of whom were men. It increases the risk of heart disease and if left untreated, it can lead to nonalcoholic steatohepatitis (NASH), a condition causing inflamed liver. More than 40% of people with NAFLD develop NASH which can lead to scarring of the liver. Severe liver scarring, known as cirrhosis, increases the risk of liver cancer.
The most widely used treatment for NASH is to eliminate potential causes and risk factors such as weight loss and treatment for hyperglycemia or dyslipidemia. A study published by the National Center for Biotechnology Information in 2015, suggests that thiazolidinediones and vitamin E can help correct biochemical and histologic abnormalities in NASH.
Moreover, no medicines have been approved to treat NASH so far. However, researchers are developing medicines to improve the conditions. According to the National Institute of Diabetes and Digestive and Kidney Diseases, some studies suggest that pioglitazone (Actos), a medicine for type 2 diabetes, can improve NASH in people non-diabetic patients.
Companies in the market are focusing on extensive research to develop medicine for NASH treatment. For instance, in 2017, Gilead Sciences, Inc. announced results from a Phase 2, randomized, placebo-controlled trial evaluating two doses of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase, in patients with nonalcoholic steatohepatitis.
Browse 26 Market Data Tables and 28 Figures spread through 187 Pages and in-depth TOC on "Nonalcoholic Steatohepatitis Treatment Market, By Drug (Cenicriviroc, Elafibranor, Ocaliva, and Selonsertib), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
To know the latest trends and insights related to nonalcoholic steatohepatitis treatment market, click the link below:
Key Takeaways of the Nonalcoholic Steatohepatitis Treatment Market:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.